ABO blood group determines plasma von Willebrand factor levels: A biologic function after all?

Transfusion

Volumn 46, Issue 10, 2006, Pages 1836-1844

  Jenkins, P Vince ^a   O'Donnell, James S ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTERY THROMBOSIS; BLOOD GROUP ABO SYSTEM; CARBOHYDRATE ANALYSIS; HUMAN; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STRUCTURE ANALYSIS; VEIN THROMBOSIS;

ABO BLOOD-GROUP SYSTEM; CARBOHYDRATE SEQUENCE; GENETIC PREDISPOSITION TO DISEASE; GLYCOSYLATION; HUMANS; POLYSACCHARIDES; PROTEIN MODIFICATION, TRANSLATIONAL; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 33748926468     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2006.00975.x     Document Type: Review

References (74)

1. Garratty G. Blood groups and disease: a historical perspective. Transfus Med 2000;14:291-301.
2. Yamamoto F. Molecular genetics of ABO. Vox Sang 2000;78(Suppl 2):91-103.
3. Lowe JB. The blood group-specific human glycosyltransferases. Baillieres Clin Haematol 1993;6:465-92.
4. Oriol R, Mollicone R, Coullin P, Dalix AM, Candelier JJ. Genetic regulation of the expression of ABH and Lewis antigens in tissues. APMIS Suppl 1992;27:28-38.
5. Greenwell P. Blood group antigens: molecules seeking a function? Glycoconj J 1997;14:159-73.
6. Aird L, Bentall HH, Roberts JA. A relationship between cancer of the stomach and the ABO blood groups. Br Med J 1953;1:799-804.
7. Langman MJ. Relationship between preoperative bleeding and perforation and bleeding after operations for duodenal ulcer. Gut 1965;23:134-6.
8. O'Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med 2001;11:343-51.
9. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-5.
10. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987;69:1691-5.
11. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395-424.
12. Wagner DD, Marder VJ. Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization. J Cell Biol 1984;99:2123-30.
13. Nichols TC, Samama CM, Bellinger DA, et al. Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A 1995;92:2455-9.
14. Kaufman RJ. Post-translational modifications required for coagulation factor secretion and function. Thromb Haemost 1998;79:1068-79.
15. Girma JP, Meyer D, Verweij CL, Pannekoek H, Sixma JJ. Structure-function relationship of human von Willebrand factor. Blood 1987;70:605-11.
16. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981;57:1140-3.
17. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost 1998;79:456-65.
18. Denis C, Baruch D, Kielty CM, et al. Localization of von Willebrand factor binding domains to endothelial extracellular matrix and to type VI collagen. Arterioscler Thromb 1993;13:398-406.
19. Lankhof HH, Schiphorst ME, Bracke M, et al. A3 domain is essential for interaction of von Willebrand factor with collagen type III. Thromb Haemost 1996;75:950-8.
20. Mohri H, Fujimura Y, Shima M, et al. Structure of the von Willebrand factor domain interacting with glycoprotein Ib. J Biol Chem 1988;263:17901-4.
21. Denis C, Williams JA, Lu X, Meyer D, Baruch D. Solid-phase von Willebrand factor contains a conformationally active RGD motif that mediates endothelial cell adhesion through the alpha v beta 3 receptor. Blood 1993;82:3622-30.
22. Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 1987;262:8443-6.
23. Furlan M, Lammle B. von Willebrand factor in thrombotic thrombocytopenic purpura. Thromb Haemost 1999;82:592-600.
24. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488-94.
25. Zheng X, Chung D, Takayama TK, et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001;276:41059-63.
26. Nichols WC, Ginsburg D. von Willebrand disease. Medicine (Baltimore) 1997;76:1-20.
27. Zheng X, Majerus EM, Sadler JE. ADAMTS13 and TTP. Curr Opin Hematol 2002;9:389-94.
28. Lenting PJ, Westein E, Terraube V, et al. An experimental model to study the in vivo survival of von Willebrand factor: basic aspects and application to the R1205H mutation. J Biol Chem 2004;279:12102-9.
29. Roussi J, Turecek PL, Andre P, et al. Effects of human recombinant, plasma-derived and porcine von Willebrand factor in pigs with severe von Willebrand disease. Blood Coagul Fibrinol 1998;9:361-72.
30. Stoddart JH Jr, Andersen J, Lynch DC. Clearance of normal and type 2A von Willebrand factor in the rat. Blood 1996;88:1692-9.
31. Turecek PL, Gritsch H, Pichler L, et al. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood 1997;90:3555-67.
32. Ashwell G, Harford J. Carbohydrate-specific receptors of the liver. Annu Rev Biochem 1982;51:531-54.
33. van Genderen PJ, Prins FJ, van de Lucas IS, van Vliet HH, Michiels JJ. Decreased half-life time of plasma von Willebrand factor collagen binding activity in essential thrombocythaemia: normalization after cytoreduction of the increased platelet count. Br J Haematol 1997;99:832-6.
34. Brown SA, Eldridge A, Collins PW, Bowen DJ. Increased clearance of von Willebrand factor antigen post-DDAVP in Type 1 von Willebrand disease: is it a potential pathogenic process? J Thromb Haemost 2003 August;1 (8):1714-7.
35. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B, and H(O) structures. J Biol Chem 1992 May 5;267 (13):8723-31.
36. Matsui T, Fujimura Y, Nishida S, Titani K. Human plasma alpha 2-macroglobulin and von Willebrand factor possess covalently linked ABO(H) blood group antigens in subjects with corresponding ABO phenotype. Blood 1993;82:663-8.
37. Matsui T, Shimoyama T, Matsumoto M, et al. ABO blood group antigens on human plasma von Willebrand factor after ABO-mismatched bone marrow transplantation. Blood 1999;94:2895-900.
38. O'Donnell J, Mille-Baker B, Laffan M. Human umbilical vein endothelial cells differ from other endothelial cells in failing to express ABO blood group antigens. J Vasc Res 2000;37:540-7.
39. Brown SA, Collins PW, Bowen DJ. Heterogeneous detection of A-antigen on von Willebrand factor derived from platelets, endothelial cells and plasma. Thromb Haemost 2002;87:990-6.
40. Sodetz JM, Paulson JC, McKee PA. Carbohydrate composition and identification of blood group A, B, and H oligosaccharide structures on human Factor VIII/von Willebrand factor. J Biol Chem 1979;254:10754-60.
41. Samor B, Michalski JC, Mazurier C, et al. Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconj J 1989;6:263-70.
42. Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. Br J Haematol 1999;105:110-6.
43. Orstavik KH, Magnus P, Reisner H, et al. Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985;37:89-101.
44. McCallum CJ, Peake IR, Newcombe RG, Bloom AL. Factor VIII levels and blood group antigens. Thromb Haemost 1983;50:757.
45. Mohanty D, Ghosh K, Marwaha N, et al. Major blood group antigens - a determinant of factor VIII levels in blood? Thromb Haemost 1984;51:414.
46. Shima M, Fujimura Y, Nishiyama T, et al. ABO blood group genotype and plasma von Willebrand factor in normal individuals. Vox Sang 1995;68:236-40.
47. Souto JC, Almasy L, Muniz-Diaz E, et al. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000;20:2024-8.
48. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002;22:335-41.
49. Miller CH, Haff E, Platt SJ, et al. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003;1:2191-7.
50. Medalie JH, Levene C, Papier C, et al. Blood groups, myocardial infarction and angina pectoris among 10,000 adult males. N Engl J Med 1971;285:1348-53.
51. Orstavik KH, Kornstad L, Reisner H, Berg K. Possible effect of secretor locus on plasma concentration of factor VIII and von Willebrand factor. Blood 1989;73:990-3.
52. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol 2002;116:350-6.
53. Schleef M, Strobel E, Dick A, et al. Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 2005;128:100-7.
54. O'Donnell J, Boulton FE, Laffan MA. The relationship between plasma concentration of alpha2-macroglobulin and ABO blood group. Thromb Haemost 2002;88:167-8.
55. O'Donnell J, Laffan MA. Dissociation of ABH antigen expression from von Willebrand factor synthesis in endothelial cell lines. Br J Haematol 2003;121:928-31.
56. Sweeney JD, Hoernig LA. Intraplatelet von Willebrand factor and ABO blood group. Thromb Res 1992;68:393-8.
57. Sodetz JM, Pizzo SV, McKee PA. Relationship of sialic acid to function and in vivo survival of human factor VIII/von Willebrand factor protein. J Biol Chem 1977;252:5538-46.
58. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003;1:33-40.
59. O'Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA. Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 2005;106:1988-91.
60. Titani K, Kumar S, Takio K, et al. Amino acid sequence of human von Willebrand factor. Biochemistry 1986;25:3171-84.
61. Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease. Blood 1998;91:2032-44.
62. Petrescu AJ, Milac AL, Petrescu SM, Dwek RA, Wormald MR. Statistical analysis of the protein environment of N-glycosylation sites: implications for occupancy, structure, and folding. Glycobiology 2004;14:103-14.
63. Bowen DJ. Increased susceptibility of von Willebrand factor to proteolysis by ADAMTS13: should the multimer profile be normal or type 2A? Blood 2004;103:3246.
64. Ellies LG, Ditto D, Levy GG, et al. Sialyltransferase ST3Gal-IV operates as a dominant modifier of hemostasis by concealing asialoglycoprotein receptor ligands. Proc Natl Acad Sci U S A 2002;99:10042-7.
65. Mohlke KL, Purkayastha AA, Westrick RJ, et al. Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell 1999;96:111-20.
66. Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, et al. The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A. Thromb Haemost 2000;83:65-9.
67. Sarode R, Goldstein J, Sussman II, Nagel RL, Tsai HM. Role of A and B blood group antigens in the expression of adhesive activity of von Willebrand factor. Br J Haematol 2000;109:857-64.
68. Carew JA, Quinn SM, Stoddart JH, Lynch DC. O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b. J Clin Invest 1992;90:2258-67.
69. Federici AB, De Elder JH, Ruggeri ZM, Zimmerman TS. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. J Clin Invest 1984;74:2049-55.
70. Kao KJ, Pizzo SV, McKee PA. Factor VIII/von Willebrand protein: modification of its carbohydrate causes reduced binding to platelets. J Biol Chem 1980;255:10134-9.
71. Berkowitz SD, Federici AB. Sialic acid prevents loss of large von Willebrand factor multimers by protecting against amino-terminal proteolytic cleavage. Blood 1988;72:1790-6.
72. Chng WJ, Yip CY, Baliwag MB, Liu TC. Differential effect of the ABO blood group on von Willebrand factor collagen binding activity and ristocetin cofactor assay. Blood Coagul Fibrinol 2005;16:75-8.
73. Eastlund T. The histo-blood group ABO system and tissue transplantation. Transfusion 1998;38:975-88.
74. Feizi T. Blood group antigens and gastric cancer. Med Biol 1982;60:7-11.